ERBB2 and breast cancer: For all cases, luminal A was the most dominant subtype constituting 48%, while luminal B and HER2-enriched subtypes both accounted for 20% with a difference in distribution between the groups, and triple-negative BC was present only in the H. group, which formed only 12% of the studied population.